Diurnal announces collaboration partner Phoqus to progress

13-Oct-2006

Biofusion plc announced that Phoqus Group plc intends to raise approximately £3 million, gross of expenses to progress Chronocort into Phase II clinical trials for the treatment of adrenal insufficiency. Chronocort, which has European Orphan Medicinal Product designation, is being developed in collaboration with Biofusion subsidiary company Diurnal Limited and is expected to be ready for market in the next two to three years.

Chronocort is a modified release formulation of hydrocortisone to treat adrenal insufficiency. The product is designed to mimic the natural rhythm of hormone levels in the body which is considered important in controlling disease symptoms and reducing unwanted side effects.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance